Start Your Search
P1.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 206)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
P1.01-027 - Prognostic Impact of Cytological Fluid Tumor Markers in Non-Small Cell Lung Cancer (ID 2700)
09:30 - 17:00 | Author(s): S.R. Hong
Serum tumor markers CYFRA 21-1, CEA, and squamous cell carcinoma antigen (SCCA) are useful in non-small cell lung cancer (NSCLC) diagnosis and prognosis. Cytologic tumor markers obtained during needle aspiration biopsy (NAB) of lung lesions help in NSCLC diagnosis. This study investigated the incremental prognostic value of cytologic tumor markers compared to serum tumor markers.
This prospective study included 253 patients diagnosed with NSCLC by NAB with cytologic tumor marker analysis. Cytologic CYFRA 21-1, CEA, SCCA and serum counterparts were followed up for survival analysis. Optimal cut-off values for each tumor marker were obtained for overall survival (OS) and progression free survival (PFS) analysis.
All patients were followed up for median 22.8 months. Using cut-off value of 0.44ng/ml for C-SCCA, 2.0ng/ml for S-SCCA, and 3.3ng/ml for S-CYFRA, multivariate analysis revealed that high S-CYFRA (Hazard ratio (HR): 1.573), high S-SCCA (HR: 1.999), and high C-SCCA (HR: 1.744) were independent predictive factors for OS. The 3 year overall survival was 55% vs 80% for high and low C-SCCA.
Cytologic tumor markers are poor prognostic factor in NSCLC patients as serum tumor markers, with C-SCCA showing a strong prognostic factor for overall survival.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.